Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06616194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06616194 · ClinicalTrials.gov record · last posted 2026-07-30

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

StatusActive, Not Recruiting
PhasePhase 3
SponsorPfizer
Started2024-11-15
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day. Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months. In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period. Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at all visits. Participants will have to complete a daily diary to record the migraine attacks.

Protocol amendment history 6 changes detected by DataLookout

2026-07-31
notable
Enrollment closed, study ongoing
2026-07-31
critical
Primary completion pushed: 2026-10-08 → 2028-08-19
2026-07-31
minor
Completion pushed: 2027-12-02 → 2029-10-13
2026-06-10
minor
Trial sites reduced: 108 → 103 locations
2026-05-15
minor
Trial sites expanded: 48 → 107 locations
2026-05-06
minor
Trial sites reduced: 107 → 48 locations
Trial Details
NCT Number NCT06616194
Lead Sponsor Pfizer
Conditions Migraine
Enrollment 200 participants
Start Date 2024-11-15
Primary Completion 2028-08-19 (estimated)
Study Completion 2029-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-30